Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

NCT: NCT05794880 · RECRUITING

NCT IDNCT05794880
StatusRECRUITING
Start Date2023-05-01
SponsorMedical College of Wisconsin (OTHER)
First posted
Last updated

Brief Summary

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑